Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

Core Insights - Adagene Inc. is set to present its lead clinical program, muzastotug, at the AACR Meeting in April 2026, highlighting its potential in cancer immunotherapy [1][4] Group 1: Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using computational biology and artificial intelligence [2] - The company has established strategic collaborations to leverage its SAFEbody precision masking technology, aiming to address unmet patient needs in cancer treatment [2] Group 2: Technology and Pipeline - Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, which are designed to enhance the safety and efficacy of antibody therapeutics [3] - The SAFEbody technology specifically targets safety and tolerability challenges by masking the binding domain of biologic therapies, allowing for tumor-specific targeting while minimizing off-tumor toxicity [3] Group 3: Clinical Programs - Muzastotug (ADG126) is a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation, currently undergoing Phase 1b/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy for microsatellite stable metastatic colorectal cancer [4] - The SAFEbody platform is validated for use across various antibody-based therapeutic modalities, including Fc empowered antibodies and antibody-drug conjugates [4]